{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:08:18Z","timestamp":1787314098284,"version":"build-2736575974"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T00:00:00Z","timestamp":1562198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T00:00:00Z","timestamp":1562198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Population factors such as age, gender, ethnicity, genotype and disease state can cause inter-individual variability in pharmacokinetic (PK) profile of drugs. Primarily, this variability arises from differences in abundance of drug metabolizing enzymes and transporters (DMET) among individuals and\/or groups. Hence, availability of compiled data on abundance of DMET proteins in different populations can be useful for developing physiologically based pharmacokinetic (PBPK) models. The latter are routinely employed for prediction of PK profiles and drug interactions during drug development and in case of special populations, where clinical studies either are not feasible or have ethical concerns. Therefore, the main aim of this work was to develop a repository of literature-reported DMET abundance data in various human tissues, which included compilation of information on sample size, technique(s) involved, and the demographic factors. The collation of literature reported data revealed high inter-laboratory variability in abundance of DMET proteins. We carried out unbiased meta-analysis to obtain weighted mean and percent coefficient of variation (%CV) values. The obtained %CV values were then integrated into a PBPK model to highlight the variability in drug PK in healthy adults, taking lamotrigine as a model drug. The validated PBPK model was extrapolated to predict PK of lamotrigine in paediatric and hepatic impaired populations. This study thus exemplifies importance of the DMET protein abundance database, and use of determined values of weighted mean and %CV after meta-analysis in PBPK modelling for the prediction of PK of drugs in healthy and special populations.<\/jats:p>","DOI":"10.1038\/s41598-019-45778-9","type":"journal-article","created":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T10:24:03Z","timestamp":1562235843000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["A repository of protein abundance data of drug metabolizing enzymes and transporters for applications in physiologically based pharmacokinetic (PBPK) modelling and simulation"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2632-8525","authenticated-orcid":false,"given":"Mayur K.","family":"Ladumor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarzoo","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravind","family":"Rachapally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarang","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Bobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. Kameswara","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praneetha","family":"Pammi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hari","family":"Kangne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Balhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sriram","family":"Ghandikota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupama","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5837-3390","authenticated-orcid":false,"given":"Vivek","family":"Nautiyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagwat","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saranjit","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,4]]},"reference":[{"key":"45778_CR1","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.xphs.2016.11.017","volume":"106","author":"B Prasad","year":"2017","unstructured":"Prasad, B., Vrana, M., Mehrotra, A., Johnson, K. & Bhatt, D. K. The promises of quantitative proteomics in precision medicine. J. Pharm. Sci. 106, 738\u2013744 (2017).","journal-title":"J. Pharm. Sci."},{"key":"45778_CR2","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s10928-016-9492-y","volume":"43","author":"C Hartmanshenn","year":"2016","unstructured":"Hartmanshenn, C., Scherholz, M. & Androulakis, I. P. Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine. J. Pharmacokinet. Pharmacodyn. 43, 481\u2013504 (2016).","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"45778_CR3","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/psp4.12203","volume":"6","author":"M Sato","year":"2017","unstructured":"Sato, M. et al. Quantitative modeling and simulation in PMDA: a Japanese regulatory perspective. CPT Pharmacometrics Syst. Pharmacol. 6, 413\u2013415 (2017).","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"45778_CR4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/cpt.1013","volume":"104","author":"M Shebley","year":"2018","unstructured":"Shebley, M. et al. Physiologically based pharmacokinetic model qualification and reporting procedures for regulatory submissions: a consortium perspective. Clin. Pharmacol. Ther. 104, 88\u2013110 (2018).","journal-title":"Clin. Pharmacol. Ther."},{"key":"45778_CR5","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/cpt.819","volume":"103","author":"DK Bhatt","year":"2018","unstructured":"Bhatt, D. K. & Prasad, B. Critical issues and optimized practices in quantification of protein abundance level to determine interindividual variability in DMET proteins by LC-MS\/MS proteomics. Clin. Pharmacol. Ther. 103, 619\u2013630 (2018).","journal-title":"Clin. Pharmacol. Ther."},{"key":"45778_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1124\/dmd.111.042259","volume":"40","author":"S Ohtsuki","year":"2012","unstructured":"Ohtsuki, S. et al. Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab. Dispos. 40, 83\u201392 (2012).","journal-title":"Drug Metab. Dispos."},{"key":"45778_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-016-0028-x","volume":"7","author":"C Xie","year":"2017","unstructured":"Xie, C. et al. LC-MS\/MS quantification of sulfotransferases is better than conventional immunogenic methods in determining human liver SULT activities: implication in precision medicine. Sci. Rep. 7, 1\u201314 (2017).","journal-title":"Sci. Rep."},{"key":"45778_CR8","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1124\/dmd.115.063362","volume":"43","author":"K-w Peng","year":"2015","unstructured":"Peng, K.-w., Bacon, J., Zheng, M., Guo, Y. & Wang, M. Z. Ethnic variability in the expression of hepatic drug transporters: absolute quantification by an optimized targeted quantitative proteomic approach. Drug Metab. Dispos. 43, 1045\u20131055 (2015).","journal-title":"Drug Metab. Dispos."},{"key":"45778_CR9","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1124\/dmd.118.080523","volume":"46","author":"B Prasad","year":"2018","unstructured":"Prasad, B. et al. Abundance of phase I and II drug metabolizing enzymes in alcoholic and hepatitis C cirrhotic livers: a quantitative targeted proteomics study. Drug Metab. Dispos. 46, 943\u2013952 (2018).","journal-title":"Drug Metab. Dispos."},{"key":"45778_CR10","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1124\/dmd.113.053819","volume":"42","author":"B Prasad","year":"2013","unstructured":"Prasad, B. et al. Interindividual variability in hepatic OATPs and P-glycoprotein (ABCB1) protein expression: quantification by LC-MS\/MS and influence of genotype, age and sex. Drug Metab. Dispos. 42, 78\u201388 (2013).","journal-title":"Drug Metab. Dispos."},{"key":"45778_CR11","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/pr.2017.226","volume":"83","author":"NR Zane","year":"2018","unstructured":"Zane, N. R., Chen, Y., Wang, M. Z. & Thakker, D. R. Cytochrome P450 and flavin-containing monooxygenase families: age-dependent differences in expression and functional activity. Pediatr. Res. 83, 527\u2013535 (2018).","journal-title":"Pediatr. Res."},{"key":"45778_CR12","doi-asserted-by":"publisher","first-page":"e172","DOI":"10.1161\/CIR.0000000000000523","volume":"136","author":"G Rao","year":"2017","unstructured":"Rao, G. et al. Methodological standards for meta-analyses and qualitative systematic reviews of cardiac prevention and treatment studies: a scientific statement from the American Heart Association. Circulation 136, e172\u2013e194 (2017).","journal-title":"Circulation"},{"key":"45778_CR13","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1124\/dmd.114.058834","volume":"42","author":"B Achour","year":"2014","unstructured":"Achour, B., Barber, J. & Rostami-Hodjegan, A. Expression of hepatic drug-metabolizing cytochrome P450 enzymes and their inter-correlations: a meta-analysis. Drug Metab. Dispos. 42, 1349\u20131356 (2014).","journal-title":"Drug Metab. Dispos."},{"key":"45778_CR14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/bdd.1906","volume":"35","author":"B Achour","year":"2014","unstructured":"Achour, B., Rostami\u2010Hodjegan, A. & Barber, J. Protein expression of various hepatic uridine 5\u2032\u2010diphosphate glucuronosyltransferase (UGT) enzymes and their inter\u2010correlations: a meta\u2010analysis. Biopharm. Drug Dispos. 35, 353\u2013361 (2014).","journal-title":"Biopharm. Drug Dispos."},{"key":"45778_CR15","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1124\/dmd.114.062034","volume":"43","author":"J Bad\u00e9e","year":"2015","unstructured":"Bad\u00e9e, J., Achour, B., Rostami-Hodjegan, A. & Galetin, A. Meta-analysis of expression of hepatic organic anion transporting polypeptide (OATP) transporters in cellular systems relative to human liver tissue. Drug Metab. Dispos. 43, 424\u2013432 (2015).","journal-title":"Drug Metab. Dispos."},{"key":"45778_CR16","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1124\/dmd.116.071183","volume":"44","author":"HJ Burt","year":"2016","unstructured":"Burt, H. J. et al. Abundance of hepatic transporters in Caucasians: a meta-analysis. Drug Metab. Dispos. 44, 1550\u20131561 (2016).","journal-title":"Drug Metab. Dispos."},{"key":"45778_CR17","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1124\/dmd.107.015743","volume":"35","author":"H Perrett","year":"2007","unstructured":"Perrett, H. et al. Disparity in holoprotein\/apoprotein ratios of different standards used for immunoquantification of hepatic cytochrome P450 enzymes. Drug Metab. Dispos. 35, 1733\u20131736 (2007).","journal-title":"Drug Metab. Dispos."},{"issue":"4","key":"45778_CR18","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/cpdd.638","volume":"8","author":"Thomas M. Polasek","year":"2018","unstructured":"Polasek, T. M. et al. Toward dynamic prescribing information: codevelopment of companion model\u2010informed precision dosing tools in drug development.\u00a0Clin. Pharm. Drug Dev.\u00a08, 18\u2013425 (2019).","journal-title":"Clinical Pharmacology in Drug Development"},{"key":"45778_CR19","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.apsb.2016.04.004","volume":"6","author":"X Zhuang","year":"2016","unstructured":"Zhuang, X. & Lu, C. PBPK modeling and simulation in drug research and development. Acta Pharm. Sin. B 6, 430\u2013440 (2016).","journal-title":"Acta Pharm. Sin. B"},{"key":"45778_CR20","unstructured":"Center for Drug Evaluation and Research (CDER). Guidance for industry: physiologically based pharmacokinetic analyses-format and content, U.S. Food and Drug Administration, Silver Spring, MD (2018)."},{"key":"45778_CR21","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Guideline on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation, EMA\/CHMP\/458101\/452016, European Medicines Agency, London (2018)."},{"key":"45778_CR22","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Guideline on the investigation of drug interactions, CPMP\/EWP\/560\/595\/Rev. 561 Corr. 562**, European Medicines Agency, London (2012)."},{"key":"45778_CR23","unstructured":"Ministry of Health, Labour and Welfare Research Group. Drug interaction guideline for drug development and labeling recommendations (draft for public comment), Japanese Ministry of Health, Labour and Welfare, Tokyo (2014)."},{"key":"45778_CR24","unstructured":"Center for Drug Evaluation and Research (CDER). In vitro metabolism and transporter mediated drug-drug interaction studies, U.S. Food and Drug Administration, Silver Spring, MD (2017)."},{"key":"45778_CR25","unstructured":"Center for Drug Evaluation and Research (CDER). Guidance for industry: general clinical pharmacology considerations for pediatric studies for drugs and biological products, U.S. Food and Drug Administration, Silver Spring, MD (2014)."},{"key":"45778_CR26","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function, CPMP\/EWP\/2339\/2302, European Medicines Agency, London (2005)."},{"key":"45778_CR27","unstructured":"Committee for Medicinal Products for Human use (CHMP). Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function, EMA\/CHMP\/83874\/82014, European Medicines Agency, London (2015)."},{"key":"45778_CR28","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Guideline on the use of pharmacogenetic methodologies in the pharmacokinetic evaluation of medicinal products, EMA\/CHMP\/37646\/32009, European Medicines Agency, London (2011)."},{"key":"45778_CR29","unstructured":"Center for Drug Evaluation and Research (CDER). Guidance for industry: clinical pharmacogenomics: premarket evaluation in early-phase clinical studies and recommendations for labeling, U.S. Food and Drug Administration, Silver Spring, MD (2013)."},{"key":"45778_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.xphs.2018.10.033","volume":"108","author":"M Grimstein","year":"2019","unstructured":"Grimstein, M. et al. Physiologically based pharmacokinetic modeling in regulatory science: an update from the US Food and Drug Administration\u2019s office of clinical pharmacology. J. Pharm. Sci. 108, 21\u201325 (2019).","journal-title":"J. Pharm. Sci."},{"key":"45778_CR31","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/psp4.12134","volume":"5","author":"L Kuepfer","year":"2016","unstructured":"Kuepfer, L. et al. Applied concepts in PBPK modeling: How to build a PBPK\/PD model. CPT Pharmacometrics Syst. Pharmacol. 5, 516\u2013531 (2016).","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"45778_CR32","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/00004032-197903000-00011","volume":"36","author":"G-I Tanaka","year":"1979","unstructured":"Tanaka, G.-I., Kawamura, H. & Nakahara, Y. Reference Japanese man-I. Mass of organs and other characteristics of normal Japanese. Health\u00a0Phys. 36, 333\u2013346 (1979).","journal-title":"Health phys."},{"key":"45778_CR33","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1097\/00004032-198105000-00001","volume":"40","author":"G-I Tanaka","year":"1981","unstructured":"Tanaka, G.-I., Kawamura, H. & Nomura, E. Reference Japanese man-II. Distribution of strontium in the skeleton and in the mass of mineralized bone. Health\u00a0Phys. 40, 601\u2013614 (1981).","journal-title":"Health Phys."},{"key":"45778_CR34","unstructured":"Wang, J., Chen, R., Zhu, H., Zhou, Y. & Ma, R. Data of anatomical physiological and metabolic characteristics for Chinese reference man. 21\u201359 (Beijing: Atomic Energy Press, 1998)."},{"key":"45778_CR35","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/00004032-199504000-00008","volume":"68","author":"S Jain","year":"1995","unstructured":"Jain, S., Metha, S., Kumar, B., Reddy, A. & Nagaratnam, A. Formulation of the reference Indian adult: anatomic and physiologic data. Health\u00a0Phys. 68, 509\u2013522 (1995).","journal-title":"Health phys."},{"key":"45778_CR36","unstructured":"IAEA. Compilation of anatomical, physiological and metabolic characteristics for a reference asian man. Country reports 2 (1998)."},{"key":"45778_CR37","unstructured":"National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey (NHANES) https:\/\/www.cdc.gov\/nchs\/nhanes\/about_nhanes.htm (2019)."},{"issue":"5","key":"45778_CR38","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/10408440390242324","volume":"33","author":"Paul S. Price","year":"2003","unstructured":"Price, P. S. et al.\u00a0Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit. Rev. Toxicol. 33, 469\u2013503 (2003).","journal-title":"Critical Reviews in Toxicology"},{"key":"45778_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0146-6453(03)00002-2","volume":"32","author":"J Valentin","year":"2002","unstructured":"Valentin, J. Basic anatomical and physiological data for use in radiological protection: reference values: ICRP Publication 89. Annals of the ICRP 32, 1\u2013277 (2002).","journal-title":"Annals of the ICRP"},{"key":"45778_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10937400802545060","volume":"12","author":"CM Thompson","year":"2009","unstructured":"Thompson, C. M. et al. Database for physiologically based pharmacokinetic (PBPK) modeling: Physiological data for healthy and health-impaired elderly. J. Toxicol. Environ. Health B Crit. Rev. 12, 1\u201324 (2009).","journal-title":"J. Toxicol. Environ. Health B Crit. Rev."},{"key":"45778_CR41","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1124\/dmd.117.076703","volume":"45","author":"B Achour","year":"2017","unstructured":"Achour, B. et al. Quantitative characterization of major hepatic UDP-glucuronosyltransferase (UGT) enzymes in human liver microsomes: comparison of two proteomic methods and correlation with catalytic activity. Drug Metab. Dispos. 45, 1102\u20131112 (2017).","journal-title":"Drug Metab. Dispos."},{"key":"45778_CR42","doi-asserted-by":"crossref","unstructured":"Chiba, K. et al. Prediction of inter-individual variability in pharmacokinetics of CYP2C19 substrates in humans. Drug Metab. Pharmacokinet, 379\u2013386 (2014).","DOI":"10.2133\/dmpk.DMPK-13-RG-137"},{"key":"45778_CR43","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1021\/acs.molpharmaceut.7b00364","volume":"14","author":"C Wegler","year":"2017","unstructured":"Wegler, C. et al. Variability in mass spectrometry-based quantification of clinically relevant drug transporters and drug metabolizing enzymes. Mol. Pharm. 14, 3142\u20133151 (2017).","journal-title":"Mol. Pharm."},{"key":"45778_CR44","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1212\/01.WNL.0000138424.33979.0C","volume":"63","author":"L Hirsch","year":"2004","unstructured":"Hirsch, L. et al. Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. Neurology 63, 1022\u20131026 (2004).","journal-title":"Neurology"},{"key":"45778_CR45","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/bcpt.13120","volume":"124","author":"SC Kim","year":"2019","unstructured":"Kim, S. C. & Kim, M. G. Meta-analysis of the influence of UGT genetic polymorphisms on lamotrigine concentration. Basic Clin. Pharmacol. Toxicol. 124, 163\u2013169 (2019).","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"45778_CR46","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1080\/00498250902745082","volume":"39","author":"U Argikar","year":"2009","unstructured":"Argikar, U. & Remmel, R. Variation in glucuronidation of lamotrigine in human liver microsomes. Xenobiotica 39, 355\u2013363 (2009).","journal-title":"Xenobiotica"},{"key":"45778_CR47","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1592\/phco.19.6.437.31052","volume":"19","author":"C Chen","year":"1999","unstructured":"Chen, C., Casale, E. J., Duncan, B., Culverhouse, E. H. & Gilman, J. Pharmacokinetics of lamotrigine in children in the absence of other antiepileptic drugs. Pharmacotherapy 19, 437\u2013441 (1999).","journal-title":"Pharmacotherapy"},{"key":"45778_CR48","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1046\/j.1365-2125.2001.01389.x","volume":"51","author":"P Marcellin","year":"2001","unstructured":"Marcellin, P. et al. Influence of cirrhosis on lamotrigine pharmacokinetics. Br. J. Clin. Pharmacol. 51, 410\u2013414 (2001).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"45778_CR49","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2165\/00003088-199325060-00003","volume":"25","author":"B Rambeck","year":"1993","unstructured":"Rambeck, B. & Wolf, P. Lamotrigine clinical pharmacokinetics. Clin. Pharmacokinet. 25, 433\u2013443 (1993).","journal-title":"Clin. Pharmacokinet."},{"key":"45778_CR50","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s13318-014-0247-0","volume":"41","author":"A Reimers","year":"2016","unstructured":"Reimers, A., Sjursen, W., Helde, G. & Brodtkorb, E. Frequencies of UGT1A4*2 (P24T) and *3 (L48V) and their effects on serum concentrations of lamotrigine. Eur. J. Drug Metab. Pharmacokinet. 41, 149\u2013155 (2016).","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"45778_CR51","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40268-016-0148-6","volume":"16","author":"S Jacob","year":"2016","unstructured":"Jacob, S. & Nair, A. B. An updated overview on therapeutic drug monitoring of recent antiepileptic drugs. Drugs R. D. 16, 303\u2013316 (2016).","journal-title":"Drugs R. D."},{"key":"45778_CR52","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.2165\/00003088-200645110-00002","volume":"45","author":"SI Johannessen","year":"2006","unstructured":"Johannessen, S. I. & Tomson, T. Pharmacokinetic variability of newer antiepileptic drugs. Clin. Pharmacokinet. 45, 1061\u20131075 (2006).","journal-title":"Clin. Pharmacokinet."},{"key":"45778_CR53","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2165\/00003088-200038030-00001","volume":"38","author":"E Perucca","year":"2000","unstructured":"Perucca, E. Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin. Pharmacokinet. 38, 191\u2013204 (2000).","journal-title":"Clin. Pharmacokinet."},{"key":"45778_CR54","unstructured":"Center for Drug Evaluation and Research (CDER). Lamictal: lamotrigine tablets & chewable dispersible tablets, U.S. Food and Drug Administration, Silver Spring, MD (2003)."},{"key":"45778_CR55","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/dmd.106.009340","volume":"34","author":"A Rowland","year":"2006","unstructured":"Rowland, A. et al. In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab. Dispos. 34, 1055\u20131062 (2006).","journal-title":"Drug Metab. Dispos."},{"key":"45778_CR56","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/cpt.1109","volume":"105","author":"DK Bhatt","year":"2018","unstructured":"Bhatt, D. K. et al. Age-and genotype-dependent variability in the protein abundance and activity of six major uridine diphosphate-glucuronosyltransferases in human liver. Clin. Pharmacol. Ther. 105, 131\u2013141 (2018).","journal-title":"Clin. Pharmacol. Ther."},{"key":"45778_CR57","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher, D., Liberati, A., Tetzlaff, J. & Altman, D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med. 151, 264\u2013269 (2009).","journal-title":"Ann. Intern. Med."},{"key":"45778_CR58","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins, J. P. & Thompson, S. G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539\u20131558 (2002).","journal-title":"Stat. Med."},{"key":"45778_CR59","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1136\/bmj.d549","volume":"342","author":"RD Riley","year":"2011","unstructured":"Riley, R. D., Higgins, J. P. & Deeks, J. J. Interpretation of random effects meta-analyses. BMJ 342, 964\u2013967 (2011).","journal-title":"BMJ"},{"key":"45778_CR60","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2307\/3001666","volume":"10","author":"WG Cochran","year":"1954","unstructured":"Cochran, W. G. The combination of estimates from different experiments. Biometrics 10, 101\u2013129 (1954).","journal-title":"Biometrics"},{"key":"45778_CR61","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Contemp. Clin. Trials 7, 177\u2013188 (1986).","journal-title":"Contemp. Clin. Trials"},{"key":"45778_CR62","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1348\/000711007X255327","volume":"62","author":"FL Schmidt","year":"2009","unstructured":"Schmidt, F. L., Oh, I. S. & Hayes, T. L. Fixed- versus random-effects models in meta-analysis: model properties and an empirical comparison of differences in results. Br. J. Math. Stat. Psychol. 62, 97\u2013128 (2009).","journal-title":"Br. J. Math. Stat. Psychol."},{"key":"45778_CR63","doi-asserted-by":"crossref","unstructured":"Abduljalil, K., Johnson, T. N. & Rostami-Hodjegan, A. Fetal physiologically-based pharmacokinetic models: systems information on fetal biometry and gross composition. Clin. Pharmacokinet.\u00a057, 1149\u20131171 (2018).","DOI":"10.1007\/s40262-017-0618-1"},{"key":"45778_CR64","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1124\/dmd.114.058099","volume":"42","author":"K Abduljalil","year":"2014","unstructured":"Abduljalil, K., Cain, T., Humphries, H. & Rostami-Hodjegan, A. Deciding on success criteria for predictability of pharmacokinetic parameters from in vitro studies: an analysis based on in vivo observations. Drug Metab. Dispos. 42, 1478\u20131484 (2014).","journal-title":"Drug Metab. Dispos."},{"key":"45778_CR65","doi-asserted-by":"crossref","unstructured":"Conner, T. M., Reed, R. C. & Zhang, T. A physiologically based pharmacokinetic model for optimally profiling lamotrigine disposition and drug-drug interactions. Eur. J. Drug Metab. Pharmacokinet. 1\u201320 (2018).","DOI":"10.1007\/s13318-018-0532-4"},{"key":"45778_CR66","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1124\/dmd.106.013359","volume":"35","author":"J Yang","year":"2007","unstructured":"Yang, J., Jamei, M., Yeo, K. R., Rostami-Hodjegan, A. & Tucker, G. T. Misuse of the well-stirred model of hepatic drug clearance. Drug Metab. Dispos. 35, 501\u2013502 (2007).","journal-title":"Drug Metab. Dispos."},{"key":"45778_CR67","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1365-2125.2004.02225.x","volume":"59","author":"S Bj\u00f6rkman","year":"2005","unstructured":"Bj\u00f6rkman, S. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br. J. Clin. Pharmacol. 59, 691\u2013704 (2005).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"45778_CR68","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejps.2018.01.009","volume":"115","author":"T Johnson","year":"2018","unstructured":"Johnson, T., Bonner, J., Tucker, G., Turner, D. & Jamei, M. Development and applications of a physiologically-based model of paediatric oral drug absorption. Eur. J. Pharm. Sci. 115, 57\u201367 (2018).","journal-title":"Eur. J. Pharm. Sci."},{"key":"45778_CR69","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1111\/j.1528-1157.1991.tb05883.x","volume":"32","author":"A Peck","year":"1991","unstructured":"Peck, A. Clinical pharmacology of lamotrigine. Epilepsia 32, S9\u2013S12 (1991).","journal-title":"Epilepsia"},{"key":"45778_CR70","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1365-2125.1997.tb00028.x","volume":"43","author":"R Wootton","year":"1997","unstructured":"Wootton, R. et al. Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers. Br. J. Clin. Pharmacol. 43, 23\u201327 (1997).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"45778_CR71","first-page":"421","volume":"60","author":"T Ker\u00e4nen","year":"2010","unstructured":"Ker\u00e4nen, T., Sorri, A., Moilanen, E. & Ylitalo, P. Effects of charcoal on the absorption and elimination of the antiepileptic drugs lamotrigine and oxcarbazepine. Arzneimittelforschung 60, 421\u2013426 (2010).","journal-title":"Arzneimittelforschung"},{"key":"45778_CR72","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s002280000146","volume":"56","author":"U Ebert","year":"2000","unstructured":"Ebert, U., Thong, N., Oertel, R. & Kirch, W. Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. Eur. J. Clin. Pharmacol. 56, 299\u2013304 (2000).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"45778_CR73","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/clpt.1987.193","volume":"42","author":"A Cohen","year":"1987","unstructured":"Cohen, A. et al. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin. Pharmacol. Ther. 42, 535\u2013541 (1987).","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45778-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45778-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45778-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T06:14:32Z","timestamp":1671257672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45778-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,4]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["45778"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-45778-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,4]]},"assertion":[{"value":"14 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"9709"}}